TMO Thermo Fisher Scientific Inc Common Stock
Sobre Thermo Fisher Scientific Inc Common Stock Visão geral da empresa da Wikipedia
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Ler mais
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
It ranked 106th on the Fortune 500 list based on its 2025 annual revenue of $44.556 billion.
History
Predecessors and merger
Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos received a PhD from MIT in mechanical engineering and Nomikos was a Harvard Business School graduate. The company focused on providing analytical and laboratory products.
Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.
On May 8, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific, and had about 30,000 employees, and reported US$9 billion in combined revenue. On November 9, 2006, the companies announced that the merger had been completed. However, the Federal Trade Commission ruled that this acquisition was anti-competitive regarding centrifugal evaporators, requiring Fisher to divest Genevac. In April 2007, Genevac was sold to Riverlake Partners LLC and the merger closed with FTC approval.
The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene).
Acquisition history
In 1990, Thermo Fisher Scientific (then known as Thermo Instrument Systems) acquired mass spectrometer manufacturer Finnigan Instrument Corporation.
In 2003, the company (then Fisher Scientific International) acquired Perbio Science, a transaction that included brands such as Pierce Biotechnology, HyClone and Endogen.
In April 2006, BioImage was acquired by Thermo Fisher Scientific. The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008. BioImage was established in 1993 as a drug discovery research unit led by Ole Thastrup within Novo Nordisk, from which it spun out of in 1999. It had specialized in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays.
In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.
In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash.
In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing. Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems. The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition.
In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs manufactures, and delivers technologies used in bioprocessing. In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September
In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.
In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction was completed a day later. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. As of 2017, the company had revenues of $20.9 billion, and was a Fortune 500 company.
In September 2018, Thermo Fisher Scientific announced it had signed a definitive agreement with Becton, Dickinson and Company (BDX) to acquire their Advanced Bioprocessing business. This BD business had annualized revenue of approximately $100 million; as of October 16, 2018, it had been integrated into Thermo Fisher's Life Sciences Solutions Segment.
In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio. In May 2019, Thermo Fisher Scientific partnered with MMJ International Holdings to manufacture drug products developed by MMJ for the treatment of multiple sclerosis and Huntington's disease. In June, the business announced it would acquire mass spectrometry software provider, HighChem.
In March 2020, Thermo Fisher Scientific received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic. Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to
support the development and production of new mRNA-based COVID-19 vaccines.
In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion. In July, the offer for Qiagen was raised from €39 to €43 per share (€11.3 billion in total). On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement.
In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies. In December the business announced it would acquire Phitonex, Inc.
In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million.
In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. PPD generated $4.7 billion in revenue during FY 2020, and this transaction, which values their company at approximately $20.9 billion. In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products.
In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. PeproTech became part of Thermo Fisher’s biosciences business and was integrated into the Life Sciences Solutions Segment.
In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6 billion from Nordic Capital. The acquisition completed in January 2023.
In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash. In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash).
In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion.
In February 2025, Thermo Fisher announced the acquisition of Solventum’s purification and filtration business for $4.1 billion.
In July 2025, Thermo Fisher added drug manufacturing capabilities in the United States through its purchase of a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.
In October 2025, Thermo Fisher announced a deal to acquire Clario Holdings—an endpoint data management solutions provider—for $8.88 billion in cash from a shareholder group including Novo Holding. The transaction was expected to close mid-2026.
Leadership
Marc N. Casper has been Chief Executive Officer of Thermo Fisher Scientific since October 2009, and was elected Chairman of the Board in February 2020. He also served as President from 2009 until March 2026. He joined the company in 2001 as President of the Life Sciences sector of Thermo Electron. Casper was named Senior Vice President in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger creating Thermo Fisher Scientific in 2006, he was named Executive Vice President and President of its Analytical Technologies business, and in 2008 he became the company’s Chief Operating Officer.
Prior to joining Thermo Fisher, Casper served as President, Chief Executive Officer and a Director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as President–Americas. He began his career as a strategy consultant at Bain & Company and later joined Bain Capital.
Partnerships
In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region.
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus.
In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration
agreement with Moderna, Inc. The collaboration was designed to scale up the
manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA
products.
In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients.
In November 2023, Thermo Fisher partnered with Flagship Pioneering, a biotechnology company. Together, they plan to create companies in the biotechnology field.
In January 2025, Thermo Fisher partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study. Using the Olink Explore platform, UKB-PPP seeks to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose, and treat diseases.
In February 2025, Thermo Fisher entered a 10-year virtual power purchase agreement (VPPA) with X-ELIO to secure 118 megawatts of solar energy, moving its European operations closer to a 100% renewable electricity goal.
In June 2025, Thermo Fisher partnered with the Regeneron Genetics Center which selected the Olink Explore platform for large-scale proteomics investigation involving nearly 200,000 patient samples aiming to unlock new insights into the dynamic biology and mechanisms of human disease.
Controversies
Xinjiang and Tibet
In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities. In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang.
In 2022, following reports that Thermo Fisher Scientific had sold products to police in the Tibet Autonomous Region, the Inter-Parliamentary Alliance on China called on governments to "investigate and suspend commercial activities with companies providing the PRC government with technologies to carry out biometric surveillance in the Uyghur Region, Tibet and elsewhere in the PRC, including the PRC state backed BGI Group and US firm Thermo Fisher." Thermo Fisher Scientific subsequently halted sales of DNA collection kits in Tibet.
HeLa cells
In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research. Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more.
In May 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit. In late July 2023, with the motion to dismiss still outstanding, the court ordered the parties to attend a settlement conference. Soon after that, settlement of the suit, with undisclosed terms, was announced.
Mexican plant
In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by the Gulf Cartel. According to Opengate Capital, the company withheld important documents and pressured employees into concealing the presence of the drug cartel.
Image manipulation
In May 2026, scientists found that a large number of images from Thermo Fisher Scientific's catalog had been manipulated, with sections of the images blanked out and duplicated with the same part of the picture copied into multiple places. The images were claimed to validate the effectiveness of antibody products which have uses including Western blots.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
TMO Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
TMO Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
| Data ex | Valor |
|---|---|
| 15 de Junho de 2026 | $0,4700 |
| 13 de Março de 2026 | $0,4700 |
| 15 de Dezembro de 2025 | $0,4300 |
| 15 de Setembro de 2025 | $0,4300 |
| 13 de Junho de 2025 | $0,4300 |
| 14 de Março de 2025 | $0,4300 |
| 13 de Dezembro de 2024 | $0,3900 |
| 13 de Setembro de 2024 | $0,3900 |
| 14 de Junho de 2024 | $0,3900 |
| 14 de Março de 2024 | $0,3900 |
| 14 de Dezembro de 2023 | $0,3500 |
| 14 de Setembro de 2023 | $0,3500 |
| 14 de Junho de 2023 | $0,3500 |
| 14 de Março de 2023 | $0,3500 |
| 14 de Dezembro de 2022 | $0,3000 |
| 14 de Setembro de 2022 | $0,3000 |
| 14 de Junho de 2022 | $0,3000 |
| 15 de Março de 2022 | $0,3000 |
| 14 de Dezembro de 2021 | $0,2600 |
| 14 de Setembro de 2021 | $0,2600 |
TMO Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 11 30,6%
- Compra 18 50,0%
- Manter 7 19,4%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
26 analistas · 2026-08-14Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $6.03 | $5.77 | 0.26% |
| 31 de Março de 2026 | $5.44 | $5.29 | 0.15% |
| 31 de Dezembro de 2025 | $6.57 | $6.51 | 0.06% |
| 30 de Setembro de 2025 | $5.79 | $5.55 | 0.24% |
| 30 de Junho de 2025 | $5.36 | $5.28 | 0.08% |
| 31 de Março de 2025 | $5.15 | $5.15 | -0.00% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | — |
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | — |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $8.21B | $7.58B | |
| R&D Expense | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1.00B | $967M | · | $754M | $692M | |
| SG&A Expense | $8.73B | $8.60B | $8.45B | $8.99B | $8.01B | $6.93B | $6.14B | $6.06B | · | $4.97B | $4.61B | |
| Operating Expenses | $36.81B | $35.54B | $36.00B | $36.52B | $29.18B | $24.42B | $20.95B | $20.57B | · | $15.82B | $14.63B | |
| Operating Income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | · | $2.46B | $2.34B | |
| Interest Expense | · | · | $1.38B | $726M | $536M | $553M | $676M | $667M | · | $469M | $415M | |
| Interest Income | $993M | $1.08B | $879M | $272M | $43M | $65M | $224M | $137M | · | $48M | $31M | |
| Other Non-op | $-12M | $12M | $-65M | $-104M | $-694M | $-76M | $-70M | $9M | · | $-13M | $-16M | |
| Pretax Income | $7.31B | $7.04B | $6.30B | $7.83B | $8.84B | $7.23B | $4.07B | $3.26B | · | $2.02B | $1.94B | |
| Income Tax | $547M | $657M | $284M | $703M | $1.11B | $850M | $374M | $324M | · | $-1M | $-44M | |
| Net Income | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | · | · | · | · | |
| EPS (Basic) | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 | $9.24 | $7.31 | · | $5.12 | $4.96 | |
| EPS (Diluted) | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | · | $5.09 | $4.92 | |
| Shares (Basic) | 377,000,000 | 382,000,000 | 386,000,000 | 392,000,000 | 394,000,000 | 396,000,000 | 400,000,000 | 402,000,000 | · | 395,000,000 | 399,000,000 | |
| Shares (Diluted) | 378,000,000 | 383,000,000 | 388,000,000 | 394,000,000 | 397,000,000 | 399,000,000 | 403,000,000 | 406,000,000 | · | 397,000,000 | 402,000,000 | |
| EBITDA | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $6.05B | · | $4.21B | $4.02B |
Balanço Patrimonial 28
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.85B | $4.01B | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B | $2.10B | · | $786M | $452M | |
| Short-term Investments | $253M | $1.56B | $3M | · | · | · | · | · | · | · | · | |
| Receivables | $8.90B | $8.19B | $8.22B | $8.12B | $7.98B | $5.74B | $4.35B | $4.14B | $3.87B | $3.05B | $2.54B | |
| Inventory | $5.42B | $4.98B | $5.09B | $5.63B | $5.05B | $4.03B | $3.37B | $3.00B | $2.72B | $2.21B | $1.99B | |
| Other Current Assets | $2.61B | $1.96B | $1.76B | $1.64B | $1.64B | $1.13B | $1.17B | $922M | $1.47B | $595M | $534M | |
| Current Assets | $28.71B | $22.14B | $24.59B | $25.23B | $20.11B | $21.96B | $11.89B | $10.62B | · | $7.02B | $5.74B | |
| PP&E (Net) | $10.56B | $9.31B | $9.45B | $9.28B | $8.33B | $5.91B | $4.75B | $4.17B | · | $2.58B | $2.45B | |
| PP&E (Gross) | $18.38B | $16.06B | $15.52B | $14.27B | $12.59B | $9.58B | $7.76B | $6.82B | · | $4.42B | $4.11B | |
| Accum. Depreciation | $7.82B | $6.75B | $6.08B | $4.99B | $4.26B | $3.67B | $3.02B | $2.65B | · | $1.84B | $1.66B | |
| Goodwill | $49.36B | $45.85B | $44.02B | $41.20B | $41.92B | $26.04B | $25.71B | $25.35B | · | $21.33B | $18.83B | |
| Intangibles | $15.84B | $15.53B | $16.67B | $17.44B | $20.11B | $12.69B | $14.01B | $14.98B | · | $13.97B | $12.76B | |
| Other Non-current Assets | $5.87B | $4.49B | $4.00B | $4.01B | $4.64B | $2.46B | $2.01B | $1.12B | $1.17B | $1.01B | $1.06B | |
| Total Assets | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Accounts Payable | $3.62B | $3.08B | $2.87B | $3.38B | $2.87B | $2.17B | $1.92B | $1.61B | · | $926M | $822M | |
| Short-term Debt | · | · | · | · | · | · | · | $693M | · | $953M | $50M | |
| Current Liabilities | $15.19B | $13.33B | $14.01B | $17.01B | $13.44B | $10.30B | $6.20B | $6.15B | · | $4.87B | $4.15B | |
| Capital Leases | $1.20B | $1.24B | $1.24B | $1.31B | $1.20B | $626M | $571M | · | · | · | · | |
| Deferred Tax | $1.49B | $1.27B | $1.92B | $2.85B | $3.84B | $1.79B | $2.19B | $2.27B | $2.71B | $2.56B | $2.62B | |
| Other Non-current Liabilities | $4.27B | $3.99B | $4.64B | $4.24B | $4.54B | $3.33B | $3.24B | $2.52B | $2.64B | $1.57B | $1.29B | |
| Long-term Debt | $39.17B | $31.07B | $34.73B | $34.28B | $34.67B | $21.73B | $17.75B | $18.99B | · | · | · | |
| Total Debt | · | · | · | · | · | $19.11B | $17.08B | $693M | · | $953M | $50M | |
| Common Stock | $445M | $444M | $442M | $441M | $439M | $437M | $434M | $432M | · | $415M | $412M | |
| Retained Earnings | $59.16B | $53.10B | $47.36B | $41.91B | $35.43B | $28.12B | $22.09B | $18.70B | $16.03B | $13.93B | $12.14B | |
| Treasury Stock | $22.31B | $19.23B | $15.13B | $12.02B | $8.92B | $6.82B | $5.24B | $3.67B | · | $2.31B | $1.01B | |
| AOCI | $-2.45B | $-2.70B | $-3.22B | $-3.10B | $-2.33B | $-2.81B | $-2.68B | $-2.50B | $-2.09B | $-2.64B | $-2.00B | |
| Stockholders' Equity | $53.41B | $49.58B | $46.73B | $43.98B | $40.79B | $34.51B | $29.68B | $27.59B | · | $21.54B | $21.35B | |
| Liabilities + Equity | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Shares Outstanding | 445,000,000 | 444,000,000 | 442,000,000 | 441,000,000 | 439,000,000 | 437,000,000 | 434,000,000 | · | · | · | · |
Fluxo de Caixa 19
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $2.27B | · | $1.76B | $1.69B | |
| Stock-based Comp | $310M | $301M | $278M | $307M | $230M | $196M | $181M | $181M | · | $133M | $125M | |
| Deferred Tax | $-639M | $-1.21B | $-1.30B | $-997M | $-645M | $-269M | $-499M | $-474M | · | $-639M | $-600M | |
| Amort. of Intangibles | $1.73B | $1.95B | $2.34B | $2.40B | $1.76B | $1.67B | $1.71B | $1.74B | · | $1.38B | $1.31B | |
| Restructuring | $197M | $97M | $194M | $68M | $37M | $51M | $52M | $88M | · | $167M | $90M | |
| Operating Cash Flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B | · | $3.26B | $2.94B | |
| CapEx | $1.52B | $1.40B | $1.48B | $2.24B | $2.52B | $1.47B | $926M | $758M | · | $444M | $423M | |
| Investing Cash Flow | $-4.05B | $-5.84B | $-5.14B | $-2.16B | $-21.93B | $-1.51B | $-1.49B | $-1.25B | · | $-5.52B | $-1.09B | |
| Debt Issued | $7.76B | $1.20B | $5.94B | $3.19B | $18.14B | $3.46B | $5.64B | $690M | · | $7.60B | $1.80B | |
| Net Debt Issued | $5.35B | $-2.40B | $160M | $2.82B | $6.40B | $2.75B | $-722M | $-1.36B | · | $3.27B | $-1.98B | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | $0 | $0 | |
| Stock Repurchased | $3.00B | $4.00B | $3.00B | $3.00B | $2.00B | $1.50B | $1.50B | $500M | · | $1.25B | $500M | |
| Net Stock Activity | $-3.00B | $-4.00B | $-3.00B | $-3.00B | $-2.00B | $-1.50B | $-1.50B | $-500M | · | $-1.25B | $-500M | |
| Dividends Paid | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M | |
| Financing Cash Flow | $1.80B | $-6.79B | $-3.62B | $-2.81B | $6.58B | $959M | $-3.12B | $-2.24B | · | $2.76B | $-2.62B | |
| Net Change in Cash | $5.84B | $-4.06B | $-440M | $4.05B | $-5.84B | $7.91B | $305M | $756M | · | $345M | $-898M | |
| Taxes Paid | $1.78B | $1.83B | $1.48B | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | · | $2.71B | $2.39B | |
| Levered FCF | · | · | $5.61B | $6.25B | $6.32B | $6.33B | $3.43B | $3.18B | · | $2.24B | $1.97B |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 15.5% | · | 13.4% | 13.8% | |
| Net Margin | 15.0% | 14.8% | 13.9% | 15.5% | 19.7% | · | · | · | · | · | · | |
| Pretax Margin | 16.4% | 16.4% | 14.7% | 17.4% | 22.6% | 22.4% | 15.9% | 13.4% | · | 11.1% | 11.4% | |
| EBITDA Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 24.8% | · | 23.0% | 23.7% | |
| ROA | 6.5% | 6.4% | 6.1% | 7.2% | 9.4% | · | · | · | · | · | · | |
| ROE | 13.0% | 13.2% | 13.1% | 16.4% | 19.9% | · | · | · | · | · | · | |
| ROIC | 13.4% | 13.4% | 14.0% | 17.4% | 21.5% | 12.8% | 8.9% | 12.0% | · | 10.9% | 11.2% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 1.7 | 1.8 | 1.5 | 1.5 | 2.1 | 1.9 | 1.7 | · | 1.4 | 1.4 | |
| Quick Ratio | 1.3 | 1.0 | 1.2 | 1.0 | 0.9 | 1.6 | 1.1 | 1.0 | · | 0.8 | 0.7 | |
| Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | 0.0 | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | · | · | · | · | |
| Interest Coverage | · | · | 5.0 | 11.6 | 18.7 | 14.1 | 6.8 | 5.7 | · | 5.2 | 5.6 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | · | 3.9 | 3.9 | |
| Receivables Turnover | 5.2 | 5.2 | 5.2 | 5.6 | 5.7 | 6.4 | 6.0 | 6.1 | · | 6.5 | 6.8 |
Taxas de Crescimento 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | 0.05% | -4.6% | 14.5% | 21.7% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.27% | 3.0% | 10.0% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 7.3% | 7.0% | -12.4% | -9.4% | 21.9% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 0.21% | -5.3% | -1.1% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.1% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 5.8% | 5.7% | -13.9% | -9.9% | 21.2% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.2% | -6.4% | -2.0% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 1.0% | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 13.5% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 12
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Net Income TTM | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | $1.48B | · | $1.48B | $1.48B | |
| Market Cap | $257.86B | $230.98B | $234.61B | $242.85B | · | · | · | · | · | · | · | |
| P/E | 32.7 | 31.5 | 34.4 | 31.2 | 34.3 | 29.2 | 35.4 | 30.9 | · | 27.7 | 28.8 | |
| P/S | 5.8 | 5.4 | 5.5 | 5.4 | · | · | · | · | · | · | · | |
| P/B | 4.8 | 4.7 | 5.0 | 5.5 | · | · | · | · | · | · | · | |
| P / Cash Flow | 33.0 | 26.7 | 27.9 | 26.5 | · | · | · | · | · | · | · | |
| P / FCF | 41.0 | 31.8 | 33.9 | 35.1 | · | · | · | · | · | · | · | |
| Dividend Yield | 0.25% | 0.25% | 0.22% | 0.19% | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | 2.9% | 3.2% | 2.9% | 3.4% | 2.8% | 3.2% | · | 3.6% | 3.5% | |
| Payout Ratio | 9.5% | 9.2% | 8.8% | 6.5% | 5.1% | · | · | · | · | · | · | |
| Annual Payout | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.86B | $10.36B | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B | $10.57B | $10.71B | $11.45B | |
| R&D Expense | $364M | $336M | $357M | $346M | $352M | $342M | $374M | $346M | $339M | $331M | $327M | $319M | $346M | $391M | |
| SG&A Expense | $2.33B | $2.18B | $2.35B | $2.16B | $2.14B | $2.08B | $2.20B | $2.10B | $2.11B | $2.18B | $2.13B | $2.05B | $2.12B | $2.30B | |
| Operating Expenses | $9.91B | $9.14B | $9.96B | $9.18B | $9.02B | $8.65B | $9.38B | $8.76B | $8.72B | $8.68B | $9.03B | $8.71B | $9.15B | $9.59B | |
| Operating Income | $2.09B | $1.86B | $2.25B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B | $1.82B | $1.66B | $1.85B | $1.86B | $1.56B | $1.86B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $363M | · | $359M | $300M | · | |
| Interest Income | $207M | $233M | $259M | $234M | $297M | $203M | $227M | $277M | $295M | $279M | $309M | $246M | $146M | $150M | |
| Other Non-op | $31M | $-9M | $6M | $-2M | $-19M | $3M | $13M | $-16M | $5M | $10M | $-33M | $14M | $-46M | $35M | |
| Pretax Income | $1.92B | $1.73B | $2.15B | $1.83B | $1.71B | $1.62B | $1.94B | $1.74B | $1.76B | $1.59B | $1.74B | $1.76B | $1.36B | $1.78B | |
| Income Tax | $167M | $70M | $153M | $207M | $92M | $95M | $149M | $99M | $128M | $281M | $133M | $53M | $46M | $173M | |
| Net Income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B | $1.55B | $1.33B | $1.65B | $1.70B | $1.29B | $1.57B | |
| EPS (Basic) | $4.68 | $4.44 | $5.22 | $4.28 | $4.28 | $3.99 | $4.80 | $4.26 | $4.05 | $3.47 | $4.21 | $4.44 | $3.34 | $4.03 | |
| EPS (Diluted) | $4.68 | $4.43 | $5.21 | $4.27 | $4.28 | $3.98 | $4.78 | $4.25 | $4.04 | $3.46 | $4.20 | $4.42 | $3.32 | $4.01 | |
| Shares (Basic) | 371,000,000 | 372,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 378,000,000 | -764,000,000 | 382,000,000 | 382,000,000 | 382,000,000 | 0 | 386,000,000 | 386,000,000 | 0 | |
| Shares (Diluted) | 371,000,000 | 373,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 379,000,000 | -768,000,000 | 384,000,000 | 383,000,000 | 384,000,000 | 0 | 388,000,000 | 388,000,000 | -1,000,000 | |
| EBITDA | $2.09B | $1.86B | · | $1.94B | $1.83B | $1.72B | · | $1.84B | $1.82B | $1.66B | · | $1.86B | $1.56B | · |
Balanço Patrimonial 26
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.06B | $3.25B | $9.85B | $1.98B | $4.58B | $4.13B | $4.01B | $4.64B | $7.07B | $5.50B | · | $6.15B | $3.48B | · | |
| Short-term Investments | $0 | $2M | $253M | $1.56B | $1.81B | $1.81B | $1.56B | $2.00B | $1.75B | $1.75B | · | · | · | · | |
| Receivables | $9.45B | $9.20B | $8.90B | $8.91B | $8.59B | $8.46B | $8.19B | $8.26B | $7.94B | $7.93B | · | $8.37B | $7.92B | · | |
| Inventory | $5.63B | $5.50B | $5.42B | $5.75B | $5.56B | $5.22B | $4.98B | $5.43B | $5.20B | $5.13B | · | $5.40B | $5.66B | · | |
| Other Current Assets | $2.54B | $2.68B | $2.61B | $2.47B | $2.60B | $2.39B | $1.96B | $1.91B | $2.02B | $1.90B | · | $1.70B | $1.77B | · | |
| Current Assets | $23.36B | $22.32B | $28.71B | $22.30B | $24.58B | $23.38B | $22.14B | $23.78B | $25.48B | $23.64B | · | $23.09B | $20.21B | · | |
| PP&E (Net) | $10.76B | $10.66B | $10.56B | $10.18B | $9.63B | $9.33B | $9.31B | $9.41B | $9.28B | $9.32B | · | $9.17B | $9.35B | · | |
| PP&E (Gross) | · | · | $18.38B | · | · | · | $16.06B | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $7.82B | · | · | · | $6.75B | · | · | · | · | · | · | · | |
| Goodwill | $54.83B | $55.19B | $49.36B | $49.29B | $47.25B | $46.49B | $45.85B | $46.73B | $43.84B | $43.84B | $44.02B | $43.58B | $43.14B | $41.20B | |
| Intangibles | $18.61B | $19.15B | $15.84B | $16.24B | $15.15B | $15.32B | $15.53B | $16.26B | $15.52B | $16.05B | · | $17.09B | $17.97B | · | |
| Other Non-current Assets | $5.62B | $5.97B | $5.87B | $5.02B | $4.62B | $4.52B | $4.49B | $4.18B | $4.38B | $4.24B | · | $4.12B | $3.98B | · | |
| Total Assets | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.66B | $97.15B | |
| Accounts Payable | $3.27B | $3.34B | $3.62B | $3.12B | $2.98B | $3.05B | $3.08B | $2.61B | $2.55B | $2.56B | · | $2.51B | $2.80B | · | |
| Current Liabilities | $15.07B | $14.62B | $15.19B | $14.89B | $12.72B | $13.17B | $13.33B | $14.60B | $14.77B | $13.94B | · | $14.16B | $15.88B | · | |
| Capital Leases | · | · | $1.20B | · | · | · | $1.24B | · | · | · | · | · | · | · | |
| Deferred Tax | $1.58B | $2.11B | $1.49B | $842M | $624M | $1.04B | $1.27B | $1.12B | $1.52B | $1.81B | · | $2.62B | $2.98B | · | |
| Other Non-current Liabilities | $4.54B | $4.42B | $4.27B | $4.28B | $4.27B | $3.97B | $3.99B | $4.34B | $4.39B | $4.57B | · | $4.33B | $4.23B | · | |
| Long-term Debt | $42.28B | $42.95B | $39.17B | $35.48B | $35.03B | $33.99B | $31.07B | $35.11B | $35.20B | $35.39B | · | $35.08B | $35.05B | · | |
| Common Stock | $446M | $445M | $445M | $445M | $444M | $444M | $444M | $444M | $443M | $443M | · | $442M | $441M | · | |
| Retained Earnings | $62.19B | $60.63B | $59.16B | $57.35B | $55.90B | $54.45B | $53.10B | $51.42B | $49.94B | $48.54B | · | $45.87B | $43.06B | · | |
| Treasury Stock | $26.37B | $25.36B | $22.31B | $22.31B | $21.27B | $21.27B | $19.23B | $18.23B | $18.19B | $18.19B | · | $15.12B | $15.08B | · | |
| AOCI | $-2.46B | $-2.50B | $-2.45B | $-2.80B | $-2.80B | $-2.34B | $-2.70B | $-2.48B | $-2.41B | $-2.76B | · | $-3.03B | $-3.05B | · | |
| Stockholders' Equity | $52.68B | $51.93B | $53.41B | $51.02B | $50.51B | $49.39B | $49.58B | $48.99B | $47.43B | $45.52B | · | $45.33B | $42.26B | · | |
| Liabilities + Equity | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | · | $97.06B | $94.66B | · | |
| Shares Outstanding | 446,000,000 | 445,000,000 | 445,000,000 | 445,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 443,000,000 | 443,000,000 | 442,000,000 | 442,000,000 | 441,000,000 | 441,000,000 |
Fluxo de Caixa 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $82M | $83M | $84M | $70M | $81M | $75M | $79M | $68M | $84M | $70M | $61M | $67M | $76M | $75M | |
| Deferred Tax | $-208M | $-258M | $89M | $-127M | $-322M | $-279M | $-202M | $-400M | · | · | · | · | · | · | |
| Amort. of Intangibles | $485M | $430M | $436M | $435M | $430M | $429M | $438M | $449M | $514M | $551M | $563M | $584M | $606M | $592M | |
| Restructuring | $38M | $34M | $36M | $62M | $56M | $43M | $20M | $26M | $26M | $25M | $19M | $38M | $50M | $37M | |
| Operating Cash Flow | $2.12B | $1.19B | $3.46B | $2.24B | $1.40B | $723M | $3.29B | $2.17B | $1.96B | $1.25B | $3.72B | $2.41B | $729M | $3.49B | |
| CapEx | $450M | $376M | $465M | $404M | $294M | $362M | $480M | $272M | $301M | $347M | $405M | $332M | $458M | $550M | |
| Investing Cash Flow | $164M | $-8.96B | $891M | $-4.12B | $-288M | $-527M | $20M | $-3.58B | $-253M | $-2.03B | $-376M | $-1.18B | $-3.14B | $-525M | |
| Debt Issued | $0 | $5.24B | $4.92B | $0 | $0 | $2.84B | $0 | $0 | $-1M | $1.21B | $2.48B | $3.47B | $0 | $3.19B | |
| Net Debt Issued | · | $3.83B | · | · | · | $2.00B | · | · | · | $1.21B | · | · | $0 | · | |
| Stock Repurchased | $1.00B | $3.00B | $37M | $963M | $0 | $2.00B | $1.00B | $0 | $0 | $3.00B | $0 | $0 | $3.00B | $1.00B | |
| Net Stock Activity | · | $-3.00B | · | · | · | $-2.00B | · | · | · | $-3.00B | · | · | $-3.00B | · | |
| Dividends Paid | $175M | $162M | $162M | $163M | $162M | $149M | $149M | $150M | $149M | $135M | $136M | $135M | $117M | $117M | |
| Financing Cash Flow | $-1.57B | $1.09B | $3.53B | $-632M | $-991M | $-102M | $-3.67B | $-1.19B | $-115M | $-1.82B | $-1.43B | $1.85B | $-2.59B | $2.39B | |
| Net Change in Cash | $817M | $-6.60B | $7.87B | $-2.59B | $431M | $132M | $-630M | $-2.43B | $1.58B | $-2.58B | $1.93B | $3.02B | $-5.04B | $5.60B | |
| Free Cash Flow | · | $816M | · | · | · | $361M | · | · | · | $904M | · | · | $271M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $605M | · | · | $-19M | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| Net Margin | 14.5% | 15.0% | · | 14.5% | 14.9% | 14.6% | · | 15.4% | 14.7% | 12.9% | · | 16.0% | 12.1% | · | |
| Pretax Margin | 16.0% | 15.8% | · | 16.4% | 15.7% | 15.6% | · | 16.4% | 16.7% | 15.4% | · | 16.7% | 12.7% | · | |
| EBITDA Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| ROA | 1.6% | 1.6% | · | 1.6% | 1.6% | 1.5% | · | 1.7% | 1.6% | 1.4% | · | 1.8% | · | · | |
| ROE | 3.4% | 3.3% | · | 3.2% | 3.3% | 3.2% | · | 3.5% | 3.4% | 3.0% | · | 3.8% | · | · | |
| ROIC | 3.6% | 3.4% | · | 3.4% | 3.4% | 3.3% | · | 3.5% | 3.6% | 3.0% | · | 4.0% | · | · |
Liquidez e Solvência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.5 | · | 1.5 | 1.9 | 1.8 | · | 1.6 | 1.7 | 1.7 | · | 1.6 | · | · | |
| Quick Ratio | 0.9 | 0.9 | · | 0.8 | 1.2 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 4.6 | · | 5.2 | 5.2 | · |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.98B | $43.35B | · | $42.94B | $42.36B | $41.85B | · | $42.06B | $42.15B | $42.32B | · | $42.65B | $44.17B | · | |
| Net Income TTM | $6.62B | $6.39B | · | $6.37B | $6.31B | $6.02B | · | $6.20B | $5.94B | $5.68B | · | $5.85B | $6.68B | · | |
| Market Cap | $228.81B | $210.65B | · | $206.59B | $181.28B | $222.07B | · | $272.80B | $244.98B | $257.48B | · | $223.73B | · | · | |
| P/E | 29.1 | 27.9 | · | 27.7 | 24.7 | 31.8 | · | 38.0 | 35.8 | 39.5 | · | 33.7 | 34.0 | · | |
| P/S | 5.1 | 4.9 | · | 4.8 | 4.3 | 5.3 | · | 6.5 | 5.8 | 6.1 | · | 5.2 | · | · | |
| P/B | 4.3 | 4.1 | · | 4.0 | 3.6 | 4.5 | · | 5.6 | 5.2 | 5.7 | · | 4.9 | · | · | |
| P / Cash Flow | · | 176.7 | · | · | · | 307.2 | · | · | · | 205.8 | · | · | · | · | |
| P / FCF | · | 258.1 | · | · | · | 615.2 | · | · | · | 284.8 | · | · | · | · | |
| Earnings Yield | 3.4% | 3.6% | · | 3.6% | 4.0% | 3.1% | · | 2.6% | 2.8% | 2.5% | · | 3.0% | 2.9% | · | |
| Payout Ratio | · | 9.8% | · | · | · | 9.9% | · | · | · | 10.1% | · | · | 9.1% | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Receita | $44.56B | — | — | $42.88B | — |
| Margem Operacional % | 17.4% | — | — | 17.1% | — |
| Lucro líquido | $6.70B | — | — | $6.33B | — |
| EPS Diluído | $17.74 | — | — | $16.53 | — |
Balanço Patrimonial
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 1.9 | — | — | 1.7 | — |
| Índice de Liquidez Seca | 1.3 | — | — | 1.0 | — |
Fluxo de Caixa
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $6.29B | — | — | $7.27B | — |
Últimas notícias Notícias recentes mencionando esta empresa
- Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
- Os Analistas de Wall Street Gostam da Ação da Thermo Fisher Scientific?
- Thermo Fisher Scientific Inc. (TMO) Revela Centro de Design de Bioprocessos para Desenvolver Terapias que Mudam Vidas
- Jim Cramer sobre Thermo Fisher: “Eu acho que você pode comprá-la a este nível”
- TD Cowen Reduz Preço-Alvo da Thermo Fisher (TMO), Mantém Rating de Compra
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 2.893 declarantes · $107.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 196 (-6 vs trimestre anterior) | 140 (-78 vs trimestre anterior) | 925 (-41 vs trimestre anterior) | 1.116 (+29 vs trimestre anterior) | +59.7M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $12.171.173.789 | 24.276.316 | 11,35% | Ações |
| STATE STREET CORP | $8.443.627.719 | 16.825.879 | 7,87% | Ações |
| FMR LLC | $4.526.822.682 | 9.029.086 | 4,22% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $3.572.029.397 | 7.164.352 | 3,33% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.121.552.090 | 6.226.169 | 2,91% | Ações |
| Capital World Investors | $3.106.193.041 | 6.195.370 | 2,90% | Ações |
| NORGES BANK | $2.550.871.048 | 5.087.903 | 2,38% | Ações |
| Capital Research Global Investors | $2.079.461.815 | 4.147.545 | 1,94% | Ações |
| Capital International Investors | $1.595.416.232 | 3.182.151 | 1,49% | Ações |
| Dodge & Cox | $1.531.543.498 | 3.054.778 | 1,43% | Ações |
| Fisher Asset Management, LLC | $1.461.823.432 | 2.915.715 | 1,36% | Ações |
| Grantham, Mayo, Van Otterloo & Co. LLC | $1.373.321.891 | 2.739.191 | 1,28% | Ações |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1.371.130.859 | 2.734.823 | 1,28% | Ações |
| EdgePoint Investment Group Inc. | $1.092.789.324 | 2.179.650 | 1,02% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $1.046.130.256 | 2.086.585 | 0,98% | Ações |
| Unisphere Establishment | $1.032.801.600 | 2.060.000 | 0,96% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1.009.204.590 | 2.012.934 | 0,94% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $993.831.390 | 1.982.271 | 0,93% | Ações |
| VIKING GLOBAL INVESTORS LP | $971.342.384 | 1.937.415 | 0,91% | Ações |
| FLOSSBACH VON STORCH SE | $955.579.626 | 1.905.975 | 0,89% | Ações |
| ALLIANCEBERNSTEIN L.P. | $908.857.157 | 1.849.037 | 0,85% | Ações |
| 1832 Asset Management L.P. | $863.062.662 | 1.721.443 | 0,80% | Ações |
| Clearbridge Investments, LLC | $847.834.531 | 1.691.069 | 0,79% | Ações |
| PARNASSUS INVESTMENTS, LLC | $822.024.341 | 1.639.589 | 0,77% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $768.919.799 | 1.533.667 | 0,72% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $667.185.605 | 1.330.750 | 0,62% | Ações |
| Temasek Holdings (Private) Ltd | $583.447.171 | 1.163.729 | 0,54% | Ações |
| BlackRock, Inc. | $579.344.543 | 1.155.546 | 0,54% | Ações |
| LOOMIS SAYLES & CO L P | $571.001.278 | 1.138.905 | 0,53% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $567.301.499 | 1.131.525 | 0,53% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $541.170.491 | 1.079.405 | 0,50% | Ações |
| Pictet Asset Management Holding SA | $538.406.962 | 1.073.670 | 0,50% | Ações |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $526.019.392 | 1.049.185 | 0,49% | Ações |
| Swiss National Bank | $525.485.443 | 1.048.120 | 0,49% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $505.067.056 | 1.007.394 | 0,47% | Ações |
| Rathbones Group PLC | $504.097.425 | 1.005.460 | 0,47% | Ações |
| UBS Group AG | $503.596.066 | 1.004.460 | 0,47% | Ações |
| BANK OF AMERICA CORP /DE/ | $488.690.042 | 974.729 | 0,46% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $450.916.165 | 899.386 | 0,42% | Ações |
| Veritas Asset Management LLP | $442.637.207 | 882.873 | 0,41% | Ações |
| Focus Partners Wealth | $431.444.332 | 860.536 | 0,40% | Ações |
| FIRST MANHATTAN CO. LLC. | $422.447.886 | 841.894 | 0,39% | Ações |
| National Pension Service | $422.118.548 | 841.947 | 0,39% | Ações |
| GOLDMAN SACHS GROUP INC | $417.251.345 | 832.239 | 0,39% | Ações |
| D1 Capital Partners L.P. | $409.672.787 | 817.123 | 0,38% | Ações |
| W1M Asset Management Ltd | $408.009.352 | 814.886 | 0,38% | Ações |
| Vanguard Global Advisers, LLC | $401.921.762 | 801.663 | 0,37% | Ações |
| Legal & General Group Plc | $393.992.751 | 785.848 | 0,37% | Ações |
| BARCLAYS PLC | $383.005.951 | 763.934 | 0,36% | Ações |
| AMERIPRISE FINANCIAL INC | $373.268.191 | 744.431 | 0,35% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $369.918.950 | 737.831 | 0,34% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $365.892.528 | 729.800 | 0,34% | Ações |
| VANGUARD GROUP INC | $354.408.424 | 611.629 | 0,33% | Ações |
| California Public Employees Retirement System | $349.327.092 | 696.759 | 0,33% | Ações |
| KING LUTHER CAPITAL MANAGEMENT CORP | $339.577.646 | 677.313 | 0,32% | Ações |
| W1M Investment Management Ltd | $335.034.706 | 691.342 | 0,31% | Ações |
| NEUBERGER BERMAN GROUP LLC | $321.963.477 | 642.176 | 0,30% | Ações |
| RAYMOND JAMES FINANCIAL INC | $319.519.265 | 637.305 | 0,30% | Ações |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $314.473.046 | 627.240 | 0,29% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $309.344.243 | 616.961 | 0,29% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $307.944.336 | 614.218 | 0,29% | Ações |
| D. E. Shaw & Co., Inc. | $307.017.322 | 612.369 | 0,29% | Ações |
| JANUS HENDERSON GROUP PLC | $301.030.667 | 612.436 | 0,28% | Ações |
| RHUMBLINE ADVISERS | $297.780.694 | 593.946 | 0,28% | Ações |
| Ninety One UK Ltd | $297.641.362 | 593.668 | 0,28% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $296.956.107 | 592.301 | 0,28% | Ações |
| Mirova US LLC | $296.432.610 | 591.257 | 0,28% | Ações |
| Robeco Institutional Asset Management B.V. | $289.599.072 | 577.627 | 0,27% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $281.062.261 | 571.811 | 0,26% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $274.562.786 | 547.636 | 0,26% | Ações |
| Eurizon Capital SGR S.p.A. | $271.488.657 | 539.965 | 0,25% | Ações |
| APG Asset Management N.V. | $266.543.464 | 607.825 | 0,25% | Ações |
| Longview Partners (Guernsey) LTD | $265.608.495 | 529.776 | 0,25% | Ações |
| CITADEL ADVISORS LLC | $263.486.238 | 525.543 | 0,25% | Ações |
| Lindsell Train Ltd | $257.955.736 | 514.512 | 0,24% | Ações |
| Southpoint Capital Advisors LP | $250.680.000 | 500.000 | 0,23% | Ações |
| Qube Research & Technologies Ltd | $246.959.909 | 492.580 | 0,23% | Ações |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | $245.733.399 | 490.134 | 0,23% | Ações |
| CI INVESTMENTS INC. | $235.771.058 | 470.263 | 0,22% | Ações |
| Balyasny Asset Management L.P. | $225.425.494 | 449.628 | 0,21% | Ações |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $223.014.454 | 444.819 | 0,21% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $221.174.247 | 431.114 | 0,21% | Ações |
| ROYAL LONDON ASSET MANAGEMENT LTD | $217.246.307 | 433.314 | 0,20% | Ações |
| M&G PLC | $214.820.283 | 428.783 | 0,20% | Ações |
| Liontrust Investment Partners LLP | $211.478.390 | 364.964 | 0,20% | Ações |
| Cryder Capital Partners LLP | $210.160.586 | 419.181 | 0,20% | Ações |
| FIFTH THIRD BANCORP | $209.624.364 | 418.112 | 0,20% | Ações |
| JANE STREET GROUP, LLC | $205.206.648 | 409.300 | 0,19% | Opção de venda |
| JANE STREET GROUP, LLC | $204.905.832 | 408.700 | 0,19% | Opção de compra |
| Ensign Peak Advisors, Inc | $204.085.607 | 407.064 | 0,19% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $203.978.817 | 406.851 | 0,19% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $203.629.369 | 406.154 | 0,19% | Ações |
| AVIVA PLC | $202.744.469 | 404.389 | 0,19% | Ações |
| Navera Investment Management Ltd. | $199.087.273 | 397.439 | 0,19% | Ações |
| FIL Ltd | $198.044.720 | 395.015 | 0,18% | Ações |
| CIBC Bancorp USA Inc. | $190.068.606 | 378.891 | 0,18% | Ações |
| Alyeska Investment Group, L.P. | $188.546.957 | 376.071 | 0,18% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $187.568.351 | 373.510 | 0,17% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $180.518.000 | 360.056 | 0,17% | Ações |
| Railway Pension Investments Ltd | $179.973.199 | 358.970 | 0,17% | Ações |
Executivos da empresa 60 insiders · 29 diretores · 28 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Marijn E Dekkers | Chief Executive Officer | 17 de Agosto de 2009 F | 42.554 | 0 | 0 | $0 |
| Stephen Williamson | Retiring Sr. VP and CFO | 28 de Fevereiro de 2026 F | 32.499 | 0 | 0 | $0 |
| Kyriazi Theo Melas | VP & Chief Financial Officer | 16 de Setembro de 2004 M | 158.199 | 0 | 0 | $0 |
| Gianluca Pettiti | President & COO | 27 de Julho de 2026 S | 24.651 | 0 | 6 | $-2.582.704 |
| Mark Stevenson | Retiring Executive VP & COO | 25 de Fevereiro de 2022 F | 62.141 | 0 | 0 | $0 |
| Frederick M. Lowery | Executive Vice President | 28 de Fevereiro de 2026 F | 15.044 | 0 | 2 | $-8.154.131 |
| Michel Lagarde | Executive Vice President | 28 de Fevereiro de 2026 F | 85.151 | 0 | 5 | $-51.307.290 |
| Thomas B Shropshire Jr. | SVP and General Counsel | 25 de Fevereiro de 2026 A | 6.058 | 0 | 0 | $0 |
| Michael A Boxer | SVP and General Counsel | 10 de Março de 2025 S | 10.816 | 0 | 0 | $0 |
| Syed A. Jafry | Sr. Vice President | 26 de Fevereiro de 2021 F | 22.349 | 0 | 0 | $0 |
| Peter E Hornstra | VP & Chief Accounting Officer | 26 de Fevereiro de 2021 F | 1.962 | 0 | 0 | $0 |
| Patrick M Durbin | Senior Vice President | 28 de Agosto de 2019 F | 38.868 | 0 | 0 | $0 |
| Gregory J. Herrema | Senior Vice President | 28 de Agosto de 2019 F | 26.967 | 0 | 0 | $0 |
| Seth H Hoogasian | Sr. VP & Retiring Gen. Counsel | 28 de Fevereiro de 2018 F | 26.530 | 0 | 0 | $0 |
| Shine Daniel P | Senior Vice President | 30 de Agosto de 2017 S | 20.682 | 0 | 0 | $0 |
| Thomas W Loewald | Senior Vice President | 28 de Agosto de 2017 F | 38.133 | 0 | 0 | $0 |
| Peter M Wilver | Exec. VP & Chief Admin Officer | 15 de Março de 2017 S | 62.517 | 0 | 0 | $0 |
| Alan J Malus | Executive Vice President | 10 de Março de 2016 M | 47.286 | 0 | 0 | $0 |
| Andrew J Thomson | Senior Vice President | 26 de Agosto de 2015 F | 52.389 | 0 | 0 | $0 |
| Edward A Pesicka | Senior Vice President | 5 de Março de 2015 M | 80.641 | 0 | 0 | $0 |
| Kenneth Berger | Senior Vice President | 26 de Fevereiro de 2012 F | 36.128 | 0 | 0 | $0 |
| Stephen G Sheehan | Sr. VP, Human Resources | 5 de Março de 2010 F | 4.396 | 0 | 0 | $0 |
| Yuh-Geng Tsay | Senior Vice President | 26 de Fevereiro de 2010 F | 110.369 | 0 | 0 | $0 |
| Alexander G Stachtiaris | Sr. VP, Global Bus. Services | 5 de Março de 2008 A | 17.236 | 0 | 0 | $0 |
| Fredric T Walder | Sr. VP, Customer Excellence | 5 de Março de 2008 A | 16.730 | 0 | 0 | $0 |
| Guy Broadbent | Senior Vice President | 5 de Março de 2008 A | 31.545 | 0 | 0 | $0 |
| Joseph R Massaro | Sr. VP, Global Bus. Services | 16 de Novembro de 2007 S | 15.000 | 0 | 0 | $0 |
| SYRON RICHARD F/CA | Executive Chairman | 12 de Dezembro de 2003 S | 80.320 | 0 | 0 | $0 |
| Barry S Howe | VP, Measurement & Control | 31 de Julho de 2003 M | 23.247 | 0 | 0 | $0 |
| Alexandra R. Keith | Conselheiro | 27 de Junho de 2026 A | 2.602 | 0 | 0 | $0 |
| Dion J Weisler | Conselheiro | 27 de Junho de 2026 A | 5.446 | 0 | 0 | $0 |
| Karen S Lynch | Conselheiro | 27 de Junho de 2026 A | 1.159 | 0 | 0 | $0 |
| Scott M Sperling | Conselheiro | 27 de Junho de 2026 A | 69.479 | 0 | 0 | $0 |
| Jennifer M Johnson | Conselheiro | 27 de Junho de 2026 A | 1.403 | 0 | 0 | $0 |
| Debora L Spar | Conselheiro | 20 de Maio de 2026 A | 2.610 | 0 | 0 | $0 |
| Tyler Jacks | Conselheiro | 20 de Maio de 2026 A | 9.462 | 0 | 0 | $0 |
| Ruby R Chandy | Conselheiro | 20 de Maio de 2026 A | 3.463 | 0 | 0 | $0 |
| Nelson Chai | Conselheiro | 20 de Maio de 2026 A | 15.316 | 0 | 0 | $0 |
| Martin C Harris | Conselheiro | 20 de Maio de 2026 A | 9.532 | 0 | 0 | $0 |
| MULLEN JAMES C | Conselheiro | 21 de Maio de 2025 A | 3.393 | 0 | 0 | $0 |
| Lars Rebien Sorensen | Conselheiro | 22 de Maio de 2024 F | 9.233 | 0 | 0 | $0 |
| Jim P Manzi | Conselheiro | 3 de Fevereiro de 2023 S | 14.807 | 0 | 0 | $0 |
| Thomas J Lynch | Conselheiro | 5 de Novembro de 2021 G | 10.257 | 0 | 0 | $0 |
| Judy C Lewent | Conselheiro | 20 de Maio de 2020 A | 1.290 | 0 | 0 | $0 |
| Elaine Ullian | Conselheiro | 22 de Maio de 2019 A | 4.706 | 0 | 0 | $0 |
| William G Parrett | Conselheiro | 23 de Fevereiro de 2018 S | 11.660 | 0 | 0 | $0 |
| Michael E Porter | Conselheiro | 9 de Março de 2012 M | 14.640 | 0 | 0 | $0 |
| Peter J Manning | Conselheiro | 25 de Maio de 2011 A | 6.548 | 0 | 0 | $0 |
| Michael Adam Bell | Conselheiro | 20 de Maio de 2010 A | 8.192 | 0 | 0 | $0 |
| Stephen P Kaufman | Conselheiro | 20 de Maio de 2010 A | 9.192 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 22 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Pharmaceutical Product Development, LLC, Wildcat Acquisition Holdings (UK) Limited, Jaguar Holding Company II, Jaguar Holding Company I, LLC, Eagle Holding Company II, LLC, PPD, Inc., Thermo Fisher Scientific Powder US Holdings Corp., Thermo Fisher Scientific Inc., Fisher Scientific International LLC, Fisher Scientific Worldwide Inc., Spectra-Physics Holdings USA, LLC, Thermo Fisher Scientific Powder Holdings I Ltd, Thermo Fisher Scientific Powder Holdings II Ltd, Thermo Fisher Scientific Powder Holdings III Ltd, Thermo Fisher Scientific Powder Holdings IV Ltd, Thermo Fisher Scientific Powder US Holdings Ltd ×2 declarações | 14 de Março de 2024 | — | Declaração inicial | M&A / venda | SEC |
| Thermo Fisher Scientific Inc., Thermo Fisher (CN) Luxembourg S.à r.l. ×2 declarações | 13 de Setembro de 2017 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 30 de Junho de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 11 de Maio de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 24 de Março de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 2 de Março de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 28 de Julho de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 27 de Julho de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 28 de Outubro de 2003 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 17 de Outubro de 2002 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 16 de Outubro de 2002 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 4 de Abril de 2002 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 1 de Abril de 2002 | — | Declaração inicial | — | SEC |
| Thermo Electron Corporation IRS No. ×5 declarações | 27 de Dezembro de 2001 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 21 de Novembro de 2001 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 213 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| GDOC · Goldman Sachs ETF Trust | 4,52% | 1.847 NS | 31 de Maio de 2026 | N-PORT |
| AGIQ · Tidal Trust I | 3,99% | 918 NS | 31 de Maio de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 3,97% | 4.185 NS | 31 de Maio de 2026 | N-PORT |
| IYH · iShares Trust | 3,51% | 222.608 SH | 8 de Agosto de 2026 | Diário |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,19% | 740 NS | 30 de Abril de 2026 | N-PORT |
| PRVS · Parnassus Funds II | 3,12% | 1.576 NS | 30 de Junho de 2026 | N-PORT |
| QLTY · GMO ETF Trust | 2,94% | 269.227 NS | 31 de Maio de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 2,91% | 173.204 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 2,74% | 1.117.168 SH | 8 de Agosto de 2026 | Diário |
| IXJ · iShares Trust | 2,72% | 195.170 SH | 8 de Agosto de 2026 | Diário |
| RXL · ProShares Trust | 2,68% | 3.918 NS | 31 de Maio de 2026 | N-PORT |
| EQTY · Valued Advisers Trust | 2,66% | 72.927 NS | 30 de Abril de 2026 | N-PORT |
| TOLL · Tema ETF Trust | 2,63% | 2.616 NS | 31 de Maio de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 2,59% | 7.491 NS | 30 de Abril de 2026 | N-PORT |
| QIDX · Spinnaker ETF Series | 2,39% | 1.916 NS | 30 de Abril de 2026 | N-PORT |
| KAT · Advisors Series Trust | 2,24% | 30.779 NS | 31 de Março de 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,99% | 2.213 NS | 30 de Abril de 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,88% | 14.779 NS | 30 de Abril de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,86% | 24.566 SH | 8 de Agosto de 2026 | Diário |
| PEXL · Pacer Funds Trust | 1,67% | 1.592 NS | 30 de Abril de 2026 | N-PORT |
| FMCE · Northern Lights Fund Trust IV | 1,64% | 2.250 NS | 31 de Maio de 2026 | N-PORT |
| FMCX · Northern Lights Fund Trust IV | 1,63% | 3.902 NS | 31 de Maio de 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 1,53% | 1.276 NS | 31 de Maio de 2026 | N-PORT |
| BKDV · BNY Mellon ETF Trust II | 1,43% | 41.397 NS | 30 de Abril de 2026 | N-PORT |
| GKAT · Advisors Series Trust | 1,41% | 4.289 NS | 31 de Março de 2026 | N-PORT |
| RILA · Spinnaker ETF Series | 1,32% | 1.154 NS | 30 de Abril de 2026 | N-PORT |
| SNPV · DBX ETF Trust | 1,26% | 5.900 NS | 29 de Maio de 2026 | N-PORT |
| ALRG · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1,22% | 189 NS | 30 de Abril de 2026 | N-PORT |
| LRGC · AB Active ETFs, Inc. | 1,20% | 30.508 NS | 31 de Maio de 2026 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 1,16% | 54.333 SH | 8 de Agosto de 2026 | Diário |
| MFSG · MFS Active Exchange Traded Funds Tr… | 1,16% | 8.091 NS | 31 de Maio de 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 1,08% | 654 NS | 31 de Maio de 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 1,02% | 3.416 NS | 30 de Abril de 2026 | N-PORT |
| FFND · Northern Lights Fund Trust II | 1,02% | 2.122 NS | 31 de Maio de 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 0,88% | 233.578 SH | 8 de Agosto de 2026 | Diário |
| CAPE · DoubleLine ETF Trust | 0,86% | 4.580 NS | 31 de Março de 2026 | N-PORT |
| CRTC · DBX ETF Trust | 0,85% | 2.247 NS | 31 de Maio de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,84% | 15.398 NS | 30 de Abril de 2026 | N-PORT |
| USXF · iShares Trust | 0,84% | 21.650 SH | 8 de Agosto de 2026 | Diário |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0,81% | 28.441.000 | 8 de Agosto de 2026 | Diário |
| ZECP · Zacks Trust | 0,80% | 5.541 NS | 31 de Maio de 2026 | N-PORT |
| IWX · iShares Trust | 0,79% | 54.993 SH | 8 de Agosto de 2026 | Diário |
| TAX · EA Series Trust | 0,79% | 408 NS | 29 de Maio de 2026 | N-PORT |
| BIGY · Tidal Trust II | 0,75% | 409 NS | 30 de Abril de 2026 | N-PORT |
| OEI · Listed Funds Trust | 0,75% | 656 NS | 30 de Abril de 2026 | N-PORT |
| IVE · iShares Trust | 0,72% | 615.615 SH | 8 de Agosto de 2026 | Diário |
| FFLC · FIDELITY COVINGTON TRUST | 0,72% | 16.950 NS | 30 de Abril de 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,71% | 1.284 NS | 30 de Abril de 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,70% | 3.534.266 SH | 8 de Agosto de 2026 | Diário |
| IUSV · iShares Trust | 0,68% | 322.866 SH | 8 de Agosto de 2026 | Diário |